Skip to Content

Posts tagged with "Clinical Trials"

  • Alzheimer's Disease

    A Preventative Trial for Alzheimer’s: The Right Experiment

    Alzheimer’s disease is in the news, as the first major preventative drug trial gets underway. I salute the people who have made this happen, because we’re bound to learn a lot from the attempt, even while I fear the chances for success are not that good. A preventative trial for Alzheimer’s would, under normal circumstances… Read More
  • Cardiovascular Disease

    The CETP Saga Continues (And It’s Not Getting More Entertaining)

    Roche has halted trials of its CETP inhibitor dalcetrapib. Many will remember the Pfizer compound in this class, torcetrapib, which went down catastrophically in Phase III back in 2006. In that case, deaths in the treatment group were higher than the placebo group, which will bring you to a screeching halt every time. The generally… Read More
  • Clinical Trials

    Making Their Own ALS Drug

    We should expect to see more of this sort of thing. The Wall Street Journal headline says it all: “Frustrated ALS Patients Concoct Their Own Drug”. In this case, the drug appears to be sodium chlorite, which is under investigation as NP001 by Neuraltus Pharmaceuticals in Palo Alto. (Let’s hope that isn’t one of their… Read More
  • Biological News

    Biomarker Caution

    After that news of the Stanford professor who underwent just about every “omics” test known, I wrote that I didn’t expect this sort of full-body monitoring to become routine in my own lifetime: It’s a safe bet, though, that as this sort of thing is repeated, that we’ll find all sorts of unsuspected connections. Some… Read More
  • Clinical Trials

    Stem Cells in Texas: Quite the Business

    I (and many of the readers here) have long thought that stem cells are perhaps the most overhyped medical technology out there – at least for now. I definitely agree that the possibilities for their use are staggering, and I very much hope that some of these pan out, but the gap between those possibilities… Read More
  • Clinical Trials

    Bias in Industry-Funded Trials in Rheumatoid Arthritis?

    The title of this one says it all: “Association of industry funding with the outcome and quality of randomized controlled trials of drug therapy for rheumatoid arthritis”. Any number of critics of the drug business will tell you what that association is: we publish the good stuff and bury the bad news, right? Well, not… Read More
  • Clinical Trials

    Eschenbach Says Market, Then Test

    Ex-Intel chief Andy Grove’s idea to reform clinical trials didn’t get much of a reception around here, although (in the end) I was more receptive to the idea than many people were (the comments to the posts here followed similar lines). So it’s quite interesting to see former FDA commissioner Andy Eschenbach making what sounds… Read More
  • Clinical Trials

    Reaction to Andy Grove’s Clinical Trial Proposals

    I should mention that Science is publishing some letters that it received in response to Andy Grove’s proposal to rework the clinical trial system for drug development. Sidney Wolfe and Michael Carome of Public Citizen aren’t too happy with the idea, as you might expect. Their take, as I would reword it, could be summarized… Read More
  • Clinical Trials

    Rexahn Rides Again

    You may remember Rexahn Pharmaceuticals being mentioned here in 2010. They’re the company whose lead antidepressant drug Serdaxin showed no significance versus placebo in Phase IIa trials, and whose CEO (Dr. Ahn himself) then calmed the investment community by saying that the trial was never designed to show any statistical significance, anyw… Read More
  • Clinical Trials

    Targacept’s Antidepressant Fails, And How

    Bad news yesterday from Targacept, a small company that’s been developing an antidepressant with AstraZeneca. TC-5214 (the S enantiomer of the nicotinic ligand mecamylamine) missed its endpoints in a trial of 295 patients in Europe who had not responded to standard drug therapy – the trial started with more like 700 patients, who receiv… Read More